The patent awards Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize induced pluripotent stem cells that are virus-free and carry a much lower cancer risk Coralville, Iowa, 8 March 2022: Cellular Engineering Technologies (CET), Inc., an Iowa biotechnology company specializing in cell manufacturing and contract research services, today announced that it has received … Read more
The exclusive right grants Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize next generation bio-production of recombinant proteins, viral vectors for gene therapy and vaccines with more a more native human post-translational modification (PTM). Coralville, Iowa, 6 March 2023: Cellular Engineering Technologies (CET), Inc., an Iowa biotechnology company specializing in cell manufacturing and … Read more
DUBLIN, Ireland and Coralville, Iowa, 17 August 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Cellular Engineering Technologies (CET), a biotechnology company specializing in cell manufacturing and contract research services, today announced a non-exclusive license agreement granting CET access to ERS … Read more